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Objectives: Various approaches to myocardial reconstruction have been developed for the treatment of conges-
tive heart failure resulting from ischemic cardiomyopathy.
Methods: In this study we determined whether in situ application of polymers could reshape left ventricular ge-
ometry in a chronic rodent model of ischemic cardiomyopathy.
Results:We demonstrate that alginate and fibrin can augment left ventricular wall thickness, resulting in recon-
struction of left ventricular geometry and improvement of cardiac function. Echocardiographic results at 5 weeks
after injection of alginate demonstrated persistent improvement of left ventricular fractional shortening and pre-
vention of a continued enlargement of left ventricular dimensions, whereas fibrin glue demonstrated no progres-
sion of left ventricular negative remodeling. There was increased arteriogenesis in both the alginate and fibrin glue
groups compared with that seen in the phosphate-buffered saline control group. Infarct size was significantly re-
duced in the fibrin group (P< .05), and there was a trend toward a smaller myocardial infarction in the alginate
group.
Conclusion: Intramyocardially injected polymers can be used to reshape the aneurysmal left ventricle and might
therefore be an approach for myocardial reconstruction and a potential option in treating chronic heart failure in
human subjects.Heart failure is a major health problem in the world. Cur-
rently, therapeutic approaches in treating patients with
chronic heart failure include pharmacologic therapies, me-
chanical devices, and surgical intervention,1,2 whereas heart
transplantation remains the only viable solution for end-
stage congestive heart failure.3
Cardiac tissue engineering aims to repair damaged myo-
cardium by combing cell biology, material science, and engi-
neering principles.4,5 Myocardial infarction (MI) results in
left ventricular (LV) dilation, wall thinning, fibrosis, and re-
duced cardiac performance. One major concept of tissue en-
gineering is to take into account the effect of the extracellular
matrix (ECM). ECM scaffolds not only provide mechanical
support for tissue but also regulate cell function.6 Engi-
neered cardiac constructs composed of scaffold materials
alone or in combination with cells or growth factors have
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synthetic materials, such as polyglycolic acid, polylactic
acid, or polyethylene glycol, to biologic materials, such as
gelatin, collagen, or Matrigel (BD Biosciences, Franklin
Lakes, NJ), have been used for myocardial repair.4 Re-
cently, polymers have been shown to be effective as an in
situ tissue-engineering approach for preserving cardiac
function after an acute MI.4 Compared with a bioengineered
cardiac graft, the injectable scaffolds remain in liquid form
until after injection. After solidification in vivo, the engi-
neered biopolymer matrices have the potential to provide
mechanical support and promote cell migration and prolifer-
ation and angiogenesis.6-9
The use of tissue-engineering techniques for myocardial
repair has focused on tissue repair after an acute MI. In
this study we investigated and compared the therapeutic
effects of fibrin and alginate in a rodent model of chronic is-
chemic cardiomyopathy. We demonstrated that fibrin and
alginate alone could reconstruct a LV aneurysm, improve
cardiac function, reduce infarct scar percentage, and stimu-
late neovascularization. All these findings underline the
potential of injectable biopolymers in cardiac tissue engi-
neering for myocardial repair.
MATERIALS AND METHODS
Biopolymers
Fibrin glue (CROSSEAL Fibrin Sealant; Omrix Biopharmaceuticals,
Inc, New York, NY) consists of 2 components: biologic active components
and thrombin. Biologic active components consist mainly of human fibrin-
ogen, and thrombin is a highly specific protease that transforms thegery c January 2009
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TAbbreviations and Acronyms
ECM ¼ extracellular matrix
LV ¼ left ventricular
LVID ¼ left ventricular internal dimension
MI ¼ myocardial infarction
MRI ¼ magnetic resonance imaging
PBS ¼ phosphate-buffered saline
RGD ¼ arginine-glycine-asparagine
fibrinogen into fibrin. Alginate solution (1.5%) was made from dissolving
a high mannuronic acid (M units) alginate (ProNova LVM; FMC BioPoly-
mer, Haugesund, Norway) in 0.9%NaCl. Alginate gel formation was based
on the addition of the cross-linker solution, 102 mmol/L CaCl2.
10
Rat Chronic MI Model
The animal protocol was approved by the Committee for Animal Re-
search of the University of California San Francisco and was performed
in accordance with the recommendations of the American Association for
Accreditation of Laboratory Animal Care. This ischemia–reperfusionmodel
has been described extensively in our previous studies.9,11 Female Sprague–
Dawley rats (225–250 g) underwent 20 minutes of left anterior descending
artery occlusion, followed by reperfusion. The chest was then closed, and
the animal was allowed to recover for 5 weeks to allow for the development
of a LV aneurysm.9
Injection Operations
Sprague–Dawley rats underwent left coronary artery occlusion for 20
minutes followed by reperfusion to test the hypothesis that a fibrin or algi-
nate scaffold thickens the thinned wall of the aneurysmal left ventricle and
reshapes LV geometry. Five weeks after infarction, at which time the re-
modeling process is largely complete, injections of either the control
(0.5% bovine serum albumin in phosphate-buffered saline [PBS], n ¼
10), fibrin (n ¼ 10), or alginate (n ¼ 10) were made directly into the in-
farcted myocardium. Biopolymers were delivered as 2 components with
a Duploject applicator (Baxter, Deerfield, Ill), which holds the 2 compo-
nents fibrin and thrombin for the fibrin group and sodium alginate and cal-
cium chloride for the alginate group in separate syringes and provides
simultaneous mixing and delivery. All injections were made through 27-
gauge needles into the infarcted area of the left ventricle. The infarct area
was identified by a darker region of the LV wall with reduced contractility,
mostly within the anterior wall. Three animals from each group (n¼ 3) were
killed 24 hours after injection to examine the location and structural effect of
the polymer injections compared with control results. Animals were per-
fused with 3 mol/L KCl before death to arrest the hearts in the diastolic
phase of contraction.
To test the effects of in situ application of biopolymers in a chronic an-
eurysmal MI, the remainder of the animals (PBS, n ¼ 7; fibrin, n ¼ 7; and
alginate, n ¼ 7) were allowed to recover and survived for an additional 5
weeks after the injection (10-week-oldMI) instead of dying at 24 hours after
injection.
Echocardiography
Transthoracic echocardiographic analysis was performed on all animals
after achievement of anesthesia with isoflurane (2 L/min) 5 weeks after MI
as a baseline echocardiogram. Follow-up echocardiograms were obtained 2
days and 5 weeks after injection (10 weeks after MI). The methodology of
echocardiography used has been previously described and has demonstratedThe Journal of Thoracic and Creproducibility and accuracy in a rat MI model.9,12 Fractional shortening
(FS) as a measure of systolic function was calculated as follows:
FS ð%Þ ¼ ½ðLVIDdLVIDsÞ=LVIDd3100%;
where LVID represents the LV internal dimension, d represents diastole, and
s represents systole. An echocardiographer blinded to the treatment group
acquired the images and performed the data analysis.
Histology
After the echocardiogram at 10 weeks after MI, the rats were killed with
a pentobarbital overdose (200 mg/kg). The hearts were rapidly excised and
fresh frozen in O.C.T. freezing medium (Sakura Finetek, Torrance, Calif)
and were then sectioned into 10-mm slices. Ten representative slides were
stained with hematoxylin and eosin and Masson’s trichrome stain (Accus-
tain; Sigma, St Louis, Mo). Morphologic assessment of infarct size and
LV wall thickness was quantified based on planimetry on Masson’s tri-
chrome–stained slides with SPOT 4.0.5 software (Diagnostic Instruments,
Sterling Heights, Mich), as previously described.13 The infarcted area and
left ventricle were traced. The infarct size was determined by the scar
area divided by the LV area and was reported as a percentage of the total
left ventricle. The segmental distribution of wall thickness was determined
bymeasuring the anterior, lateral, posterior, and septal walls of each individ-
ual slide, taking the average of 10 slides for each heart.
Immunohistochemistry and Immunofluorescence
Five slides equally distributed through the infarct area were selected to
examine the extent of the inflammatory response. The slides were fixed in
acetone for 15 minutes and incubated in avidin, biotin, Sniper, and Eraser
blocking solutions (Biocare Medical, Concord, Calif). The slides were
stained with mouse anti-CD68 monocyte/macrophagemonoclonal antibody
(dilution 1:50; Chemicon International, Temecula, Calif) by using immuno-
histochemistry and diaminobenzidine stain (Animal Research Kit; DAKO,
Glostrup, Denmark). The degree of inflammatory response was semiquan-
tified by using a scoring method with scores of 0 to 4 (0, nothing; 1, few;
2, moderate; 3, much; 4, most). Another 5 slides were taken to examine an-
giogenesis in the infarct area. The slides were fixed in 1.5% formaldehyde
and then blocked with staining buffer (0.3% Triton X-100 and 2% normal
goat serum in PBS). Sections were stained with anti-a smooth muscle actin
monoclonal antibody (dilution 1:400, Sigma) and goat anti-mouse IgG2a
(dilution 1:1000; Molecular Probes, Eugene, Ore). Positive smooth muscle
staining with a visible lumen of a diameter 10 to 100 mm within the infarct
was used as the criterion to calculate arteriole density.13
Statistical Analysis
Data were reported as the mean standard deviation. A paired t test was
used for comparing baseline and postinjection echocardiographic data for
animals serving as internal controls. Echocardiographic data across groups,
histologic assessment, and immunostaining were compared by using 1-way
analysis of variance with Holm’s adjustment.
RESULTS
Acute Injection of Biopolymers Reshapes the
Aneurysmal LV Wall
In those animals killed 24 hours after injection, fibrin
glue and alginate were observed within the infarct wall.
At the location of injection, both fibrin glue and alginate
markedly altered the LV geometry, resulting in an LV cav-
ity geometry more resembling the control geometry. The re-
shaping of the LV wall was not seen with the PBS control
(Figure 1).ardiovascular Surgery c Volume 137, Number 1 181
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TFIGURE 1. Hematoxylin and eosin stain shows the presence of biopolymers in situ after 24 hours of injection. A, Infarcted myocardium treated with PBS. B,
Infarcted myocardium treated with fibrin glue. C, Infarcted myocardium treated with alginate. The black arrow indicates the location of biopolymers. Scale
bars ¼ 1.0 mm.In Situ Application of Biopolymers Improves LV
Function
The functional effects of fibrin glue and alginatewere inves-
tigated by means of echocardiographic analysis at baseline, 2
days after treatment, and 5 weeks after treatment. The sum-
mary of echocardiographic data is provided in Figure 2.
The baseline (5 weeks after MI) data indicated that there
were no difference between groups in LV function, LV inter-
nal dimensions (LVIDs), and LVwall thickness. However, 2
days after the injection of the biopolymers, improved cardiac
function and increased wall thickness were seen, and these
values were significantly increased compared with baseline
values (P< .05). The fractional shortening of the alginate
group increased from 27.5  9.3 to 41.7  11.7 (P ¼
.04), and that in the fibrin group increased from 29.3 
6.0 to 40.8  5.2 (P<.01). The anterior systolic wall thick-
ness of the alginate group increased from 1.74 0.67 to 3.60
 1.25 (P<.01), and that of the fibrin group increased from
1.90  0.54 to 3.24  0.74 (P< .01). The anterior diastolic
wall thickness also increased significantly after biopolymer
injection (alginate group, P< .01; fibrin group, P ¼ .02).
LVID during systole decreased from 0.51  0.15 to 0.36
 0.17 (P< .01) in the alginate group and from 0.51 
0.08 to 0.38  0.05 (P<.02) in the fibrin group. LVID dur-
ing diastole also decreased in both groups, from 0.73 0.10
to 0.60  0.15 (P ¼ .01) and 0.72  0.05 to 0.65  0.06
(P ¼ .01) for the alginate and fibrin groups, respectively.
Echocardiographic analysis performed at 5 weeks after in-
jection (10 weeks after MI) demonstrated a significant contin-
uation of LV dilatation in the control group and a worsening
LV function compared with that before injection. The frac-
tional shorting of the control PBS group deteriorated from
25.6  10.6 to 22.4  8.5, LV dimension enlarged (0.59 
0.11 to 0.66  0.14 cm, P systole ¼ .003; 0.79  0.06 to
0.85  0.10 cm, P diastole ¼ .02), and wall thickness de-
creased significantly (1.69 0.67 to 1.45 0.52 cm,P systole
¼ .09; 1.15 0.35 to 0.97 0.26 cm, P diastole¼ .02). Sim-
ilarly, the fibrin-treated group demonstrated deterioration of
LV fractional shortening. The fractional shortening of the182 The Journal of Thoracic and Cardiovascular Sufibrin group deteriorated to 23.1 7.5, as did LV systolic di-
mension (0.51  0.08 to 0.58  0.11 cm, P systole ¼ .02).
However, LV diastolic dimension and wall thickness did not
significantly change. In contrast, the trend with alginate was
toward improved LV function (fractional shortening from
27.5%  9.3% to 33.5%  14.1%), significantly increased
wall thickness (1.74  0.67 to 2.63  1.03 cm, P systole<
.01; 1.34 0.63 to 1.90 0.86 cm,P diastole¼ .02), and pre-
served LV dimensions.
Histology
Distinctive red muscle fibers and blue collagen deposition
were seen 10weeks afterMI in all treatment groups (Figure 3,
A–C). Tissue composed of mainly collagen covered the en-
tire LVmyocardium in all animals, demonstrating the consis-
tency and reproducibility of the MI model in this laboratory.
Figure 3, D, showed the comparison of infarct percentage 5
weeks after the treatments. The control PBS group exhibited
a 16%  3% infarction. The fibrin group had significantly
smaller infarct size (12%  2%, P ¼ .04) compared with
the control group. The alginate group also had a trend, al-
though not significant, toward reduction of infarct size
(14%  5%) compared with the control group. The LV an-
terior, lateral, posterior, and septal wall thicknesses were
measured (Figure 3, E). The LV walls of the alginate and fi-
brin groups were significantly thicker than those of the con-
trol group in the anterior, lateral, and posterior segments (P<
.05). The anterior wall of the alginate group was thicker than
that of the fibrin group, whereas there were no statistical dif-
ferences in the lateral and posterior segments. All groups had
similar wall thicknesses in septal segments.
In addition, there was detection of alginate after 5 weeks
of injection, whereas fibrin was completely reabsorbed (Fig-
ure 3, B and C), indicating the slower degradation rate and
persistence of alginate compared with fibrin.
Neovascularization
Smooth muscle a-actin staining was used as an indicator
for arterioles. Individual arterioles within the infarct areargery c January 2009
Yu et al Evolving TechnologyFIGURE 2. Echocardiographic data. *Significant difference between groups (P<.05) at 5 weeks after injection (10 weeks after myocardial infarction [MI]).
LV, Left ventricular; PBS, phosphate-buffered saline.E
Twere counted, and the total arteriole number divided by in-
farct area was reported as arteriole density. Figure 4, A
through C, showed the arteriogenesis in the middle of the in-
farct region and border zone in contrast to normal myocar-
dium. Both fibrin (24  7/mm2) and alginate (22  8/
mm2) showed significantly higher arteriole density than
PBS (14  1/mm2), indicating that biopolymers have the
ability to stimulate neovascularization in situ. Figure 5 dem-
onstrates that new arteriole formation occurs in the collagen
deposition zone of the infarcted myocardium.
Inflammation
Anti-CD68 antibody was used to detect the presence of
macrophages after 5 weeks of injection to evaluate whether
the biopolymer would cause a sustained inflammatory re-
sponse. There were CD68þcells clustering in all specimens,
indicating that inflammation might chronically exist in the
infarct area, regardless of the treatment. The fibrin was en-
tirely reabsorbed at 5 weeks after injection, and thus there
was no more traceable biopolymer scaffold to locate the im-
planted scaffold and inflammatory cells. There were few
scatteredmacrophages in the vicinity of alginate. The overallThe Journal of Thoracic and Caverage inflammatory cells in all treatment groups were
about the same, with a score lower than 1 (approximately
10% of the area), indicating that there was no significant dif-
ference between groups.
DISCUSSION
These experiments demonstrate that intramyocardial in-
jections of polymers can be used to shape the aneurysmal
LV, improve LV function, and promote preservation of
LV wall thickness. Biopolymer scaffolds mechanically pro-
vide structural support for chronic LV aneurysms and can
potentially be used as an acellular approach for myocardial
reconstruction. Previous cardiac tissue-engineering studies
focused mainly on in vitro cardiac grafts.14-16 Cells were
seeded in the polymer scaffold and subsequently patched
onto the surface of the infarcted myocardium. However, en-
gineered cardiac patches require invasive operations and are
constrained by limitation of nutrients and oxygen supply.
Unlike in vitro engineered cardiac tissue, injectable biopoly-
mers can be engineered to allow the host itself to act as a
bioreactor and reconstruct the damaged tissue in situ.ardiovascular Surgery c Volume 137, Number 1 183
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TFIGURE 3. Histologic assessment 5 weeks after injection. Masson’s trichrome staining showed the collagen deposition (blue) in the infarcted areas of the
phosphate-buffered saline (PBS; A)–, fibrin (B)–, and alginate (C)–injected groups. Black arrows indicate the existence of alginate. The infarcted percentage
of the left ventricle (LV; D) and wall thickness (E) were measured. Scale bars ¼ 1.0 mm.In addition to physically integrating into the defective
myocardium, scaffold materials must be able to withstand
the load of the tissue and provide mechanical strength.17,18
Jackson and colleagues19 applied a modified Laplace law
calculation of wall stress on an ovine anteroapical MI model.
The results indicated that geometric changes cause increased
dynamic wall stress, which likely contributes to border-zone
expansion and remodeling. The introduction of biopolymers
into the thin LV wall alters the geometry of the aneurysmal
myocardium and potentially decreases myocardial stress,
resulting in decreased dilatation of the left ventricle. Interest-
ingly, the present results corroborate results from computer
modeling studies that indicate implanting noncontractile
materials into damaged myocardium might introduce bene-
ficial effects. Wall and associates20 used a novel finite-
element analysis to predict the effect of injection of amaterial
into the myocardium. Their results indicate that the injection
of a small volume of noncontractile material into infarcted
myocardium can decrease end-systolic fiber stress. More-
over, in the infarct injection improves ejection fraction and
the stroke volume/end-diastolic volume relationship but
has no effect on the Starling relationship.
The histologic and echocardiographic results show that
both fibrin and alginate are able to restore the geometry of
a chronic aneurysmal left ventricle and increase LV function
2 days after injection of the biopolymer. The long-term184 The Journal of Thoracic and Cardiovascular Surincrease in LV fractional shortening appeared to be at least
partially related to the persistence of the polymer, presum-
ably providing sustained physical support. At 5 weeks after
the injection of fibrin glue, LV fractional shortening was
similar to control LV fractional shortening. Histologic anal-
ysis revealed the persistence of alginate, whereas fibrin glue
had been reabsorbed (Figure 3). Evidence supporting the no-
tion that fibrin has a beneficial effect, even after it is reab-
sorbed, is the preservation of LV wall thickness and
diastolic LV dimensions.
The ischemia–reperfusion rat model of MI is a frequently
used model for assessing ischemic preconditioning, cardio-
protective drugs, and MI remodeling.21-23 The ischemia–
reperfusion MI produces a more mottled infarct compared
with a transmural total ligationMI and is clinically represen-
tative of anMI seen with a reperfused coronary vessel.24 The
aneurysms produced by ischemia–reperfusion are located ei-
ther at the apex or on the anterior surface, as commonly seen
in patients with an anterior MI.25 The ischemia–reperfusion
rat model has been used to investigate the efficacy of cells
and polymers for myocardial reconstruction and can be
used as an initial model to test tissue-engineering strategies
for myocardial repair and regeneration.11 However, the
altering effects of biopolymers on the material properties
of the ventricular wall are more easily tested in large-animal
MI models.gery c January 2009
Yu et al Evolving TechnologyFIGURE 4. Increased arteriole density in the infarcted area. Smooth muscle actin staining showed visible arterioles of the phosphate-buffered saline
(PBS) (A), fibrin (B), and alginate (C) groups. Quantitative analysis of arteriole density is presented in panel D. Scale bars ¼ 100 mm.TRecently, magnetic resonance imaging (MRI) tagging
techniques were exploited on tracking LV wall motion and
stress/strain distribution of the LV wall. Walker and co-
workers26 evaluated end-diastolic stress on a sheep model
after linear repair of LV aneurysm with MRI-based finite-
element stress analysis. A potential future study is to examine
the effect of biomaterials after MI with this MRI technique.
Ideally, biopolymer scaffolds should both physically re-
side in and interact with the host tissue. Biomaterials not
only coexist with the tissue but can also influence the cardiac
microenvironment at a molecular level, which is critical for
tissue regeneration.27 Previous studies in our laboratory
demonstrated that fibrin glue enhanced angiogenesis in an
acute MI model.13 In this chronic MI study, we found that
fibrin glue stimulated new blood vessel formation, as seen
in previous acute studies. Interestingly, alginate also pro-
moted angiogenesis, although not as dramatically as fibrin
glue. This result implies that even after the pathologic re-
modeling process, the introduction of matrix materials canThe Journal of Thoracic andstill influence cell activities, such as cell recruitment, migra-
tion, and proliferation.
The mechanisms of the angiogenic effect of fibrin might
be due to its molecular properties.28 Fibrin has binding do-
mains for various growth factors, such as fibroblast growth
factor, which is an angiogenic factor. Moreover, the fibrin
fragment E has been shown to stimulate neovascularization
in vitro.29 Fibrin glue also contains an arginine-glycine-
asparagine (RGD) sequence; RGD is a ubiquitous cell adhe-
sion ligand that not only binds to integrins on cell surfaces
but can also activate downstream signaling pathways.
RGD activates a5b3 integrin, which is involved in the activa-
tion of vascular endothelial growth factor receptor30; fibrin-
ogen without RGD sequences does not to induce
angiogenesis.31
Alginate is composed of simple linear polysaccharide co-
polymers and has been widely applied in the food and phar-
maceutical industries.32 The lack of interaction between
alginate and mammalian cells might be the major limitationEFIGURE 5. Arterioles in the collagen deposition area. Smooth muscle actin staining of arterioles in the infarcted zone (A) and corresponding Trichrome
staining (B). Scale bars ¼ 100 mm.Cardiovascular Surgery c Volume 137, Number 1 185
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Tfor its use in tissue engineering. Possible mechanisms of the
angiogenic effect of alginate include an inflammatory re-
sponse of the biopolymers or a mechanical matrix effect of
the biopolymer, which allows the migration of cells into
the infarcted area. The result of CD68 staining showed
that there was no difference in inflammatory assessment at
5 weeks after injection. There were inflammatory cells resid-
ing in the infarct area in all groups. The inflammatory cells
might be recruited to the infarct area, mainly because of
the injection surgery independent of treatments. Another
possible mechanism could be the effect of ischemia-induced
chemokines that regulate leukocytes recruitment during
pathophysiologic remodeling in early MI.31,33
Future studies of in situ cardiac tissue-engineering ap-
proaches need to focus on optimization of the degradation
rate and control of thematerial properties of scaffoldmaterials.
The durability of materials should be similar to the rate of tis-
sue regeneration.17 Although fibrin undergoes reabsorption,
the endogenous cells can invade into the fibrin scaffolds, se-
crete their own ECM, and perform cellular activities.34 The
degradation rate of fibrin glue can be adjusted by changing
the concentration of aprotinin, the proteinase that prevents pro-
teolytic degradation and increases the mechanical strength of
fibrin.35,36 Alginate is usually degraded by dissolution; the
compressive and shear modulus depends on the ionic concen-
tration and ratio ofG toMunits.37,38Moreover, alginate can be
modified by means of an oxidization technique, which accel-
erates the degradation rate of alginate without significantly
changing its mechanical properties.39
This study demonstrates an acellular method for treating
chronic MI with injectable fibrin or alginate. This compara-
tive study could provide guidance for selecting suitable
materials for delivering growth factors and genes or
transplanting cells. The results also indicate that a noncellu-
lar construct itself might be sufficient for cardiac function
improvement and angiogenesis.
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